YBX1/lncRNA SBF2-AS1 interaction regulates proliferation and tamoxifen sensitivity via PI3K/AKT/MTOR signaling in breast cancer cells
- PMID: 36754932
- DOI: 10.1007/s11033-023-08308-5
YBX1/lncRNA SBF2-AS1 interaction regulates proliferation and tamoxifen sensitivity via PI3K/AKT/MTOR signaling in breast cancer cells
Abstract
Background: Y-box binding protein 1 (YBX1) is a multifunctional oncoprotein that can interact with several long non-coding RNAs (lncRNAs) to regulate metastasis in malignancies including breast cancer (BC). In the present study, we demonstrated the association of YBX1 with oncogenic lncRNA SBF2-AS1 (SET-binding factor 2 antisense RNA 1) via PI3K/AKT/mTOR signaling to regulate BC cell proliferation. We further explored the involvement of the YBX1/SBF2-AS1/PI3K/AKT/mTOR axis in the restoration of tamoxifen (TAM) sensitivity.
Methods and results: YBX1-SBF2-AS1 association was predicted in silico and verified by RNA immunoprecipitation (RIP)-qPCR assay. Transfection experiments, Real-time RT PCR, Western blots, Phospho AKT/mTOR antibody array kit, and cell proliferation/apoptosis assays were employed to detect the YBX1/SBF2-AS1/ PI3K/AKT/mTOR axis and its effects upon TAM treatment in vitro. We identified that the YBX1 protein specifically binds to lncRNA SBF2-AS1. Our transfection experiments in MCF-7 and MDA-MB-468 cells with SBF2-AS1 silenced or overexpressed YBX1 plasmids, and their negative controls revealed that YBX1 regulates the expression of SBF2-AS1 by forming a positive feedback loop for its activation. We further demonstrated YBX1-SBF2-AS1 association exerts its effects on cell proliferation via PI3K/AKT/mTOR signaling pathway. Furthermore, we observed an increase in TAM sensitivity in BC cells after the knockdown of YBX1-SBF2-AS1 marked by decreased cell proliferation through disruption of the PI3K/AKT/mTOR axis.
Conclusion: Our study has identified a novel YBX1/SBF2-AS1/PI3K/AKT/mTOR regulatory axis which may serve as a potential target to improve the effectiveness and efficacy of TAM treatment in BC.
Keywords: Breast cancer; PI3K/AKT signaling; Tamoxifen; YBX1; ceRNA; lncRNA SBF2-AS1.
© 2023. The Author(s), under exclusive licence to Springer Nature B.V.
Similar articles
-
Inhibitory role of large intergenic noncoding RNA-ROR on tamoxifen resistance in the endocrine therapy of breast cancer by regulating the PI3K/Akt/mTOR signaling pathway.J Cell Physiol. 2019 Feb;234(2):1904-1912. doi: 10.1002/jcp.27066. Epub 2018 Aug 26. J Cell Physiol. 2019. Retraction in: J Cell Physiol. 2022 Mar;237(3):2004. doi: 10.1002/jcp.30516. PMID: 30145819 Retracted.
-
Downregulation of lncRNA ZEB1-AS1 Represses Cell Proliferation, Migration, and Invasion Through Mediating PI3K/AKT/mTOR Signaling by miR-342-3p/CUL4B Axis in Prostate Cancer.Cancer Biother Radiopharm. 2020 Nov;35(9):661-672. doi: 10.1089/cbr.2019.3123. Epub 2020 Apr 9. Cancer Biother Radiopharm. 2020. PMID: 32275162
-
MNX1-AS1 suppresses chemosensitivity by activating the PI3K/AKT pathway in breast cancer.Int J Biol Sci. 2025 May 27;21(8):3689-3704. doi: 10.7150/ijbs.104483. eCollection 2025. Int J Biol Sci. 2025. PMID: 40520020 Free PMC article.
-
The emerging role of noncoding RNAs in the PI3K/AKT/mTOR signalling pathway in breast cancer.Pathol Res Pract. 2024 Mar;255:155180. doi: 10.1016/j.prp.2024.155180. Epub 2024 Jan 30. Pathol Res Pract. 2024. PMID: 38330621 Review.
-
A Pleiotropic Role of Long Non-Coding RNAs in the Modulation of Wnt/β-Catenin and PI3K/Akt/mTOR Signaling Pathways in Esophageal Squamous Cell Carcinoma: Implication in Chemotherapeutic Drug Response.Curr Oncol. 2022 Mar 26;29(4):2326-2349. doi: 10.3390/curroncol29040189. Curr Oncol. 2022. PMID: 35448163 Free PMC article. Review.
Cited by
-
Y-Box Binding Protein 1: Unraveling the Multifaceted Role in Cancer Development and Therapeutic Potential.Int J Mol Sci. 2024 Jan 5;25(2):717. doi: 10.3390/ijms25020717. Int J Mol Sci. 2024. PMID: 38255791 Free PMC article. Review.
-
LncRNA-Protein Interactions: A Key to Deciphering LncRNA Mechanisms.Biomolecules. 2025 Jun 17;15(6):881. doi: 10.3390/biom15060881. Biomolecules. 2025. PMID: 40563521 Free PMC article. Review.
-
A Subpathway and Target Gene Cluster-Based Approach Uncovers lncRNAs Associated with Human Primordial Follicle Activation.Int J Mol Sci. 2023 Jun 23;24(13):10525. doi: 10.3390/ijms241310525. Int J Mol Sci. 2023. PMID: 37445702 Free PMC article.
-
Biological functions of 5-methylcytosine RNA-binding proteins and their potential mechanisms in human cancers.Front Oncol. 2025 Feb 7;15:1534948. doi: 10.3389/fonc.2025.1534948. eCollection 2025. Front Oncol. 2025. PMID: 39990690 Free PMC article. Review.
-
Cancer stem cells and Lon-noncRNA promotes invasion, metastasis and tumor growth in breast cancer through regulation of signaling pathway.Sci Rep. 2025 Aug 8;15(1):29021. doi: 10.1038/s41598-025-13402-8. Sci Rep. 2025. PMID: 40781106 Free PMC article.
References
-
- Bray F, Ferlay J, Soerjomataram I, Seigel R, Torre L, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424. https://doi.org/10.3322/caac.21492 - DOI - PubMed
-
- Sharma R, Sharma R, Khaket TP, Dutta C, Chakraborty B, Mukherjee TK (2017) Breast cancer metastasis: putative therapeutic role of vascular cell adhesion molecule-1. Cell Onco 40(3):199–208. https://doi.org/10.1007/s13402-017-0324-x - DOI
-
- Janz M, Harbeck N, Dettmar P, Berger U, Schmidt A, Jurchott K, Schmitt M, Royer HD (2002) Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1. Int J Cancer 97(3):278–282. https://doi.org/10.1002/ijc.1610 - DOI - PubMed
-
- Matsumoto K, Wolffe AP (1998) Gene regulation by Y-box proteins: coupling control of transcription and translation. Trends cell bio 8(8):318–323. https://doi.org/10.1016/S0962-8924(98)01300-2 - DOI
-
- Habibi G, Leung S, Law JH, Gelmon K, Masoudi H, Turbin D, Pollak M, Nielsen TO, Huntsman D, Dunn SE (2008) Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Res 10(5):1–9. https://doi.org/10.1186/bcr2156 - DOI
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous